Piccina Cintia
Known title: U.S. CCO & Country Gen ManagerCIK: 0001907199
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI. Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.
Transaction History
| AUTL | ▼ Sell | Open Market | 6,713 | $16K | 9/2/2026 | View on chart |
| AUTL | ▲ Buy | Option Exercise | 20,000 | $47K | 9/1/2026 | View on chart |
| KLRS | ▲ Buy | Grant | 147,000 | $0 | 7/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Autolus Therapeutics to Present Data at Rheumatology Conference
Autolus Therapeutics announced that an abstract has been filed for presentation at the American College of Rheumatology Convergence 2026. This event serves as a key venue for sharing clinical updates in the rheumatology field. The news provides a specific upcoming date for stakeholders to monitor potential data releases related to the company's pipeline.
Autolus Therapeutics to Present Data at Rheumatology Conference. Autolus Therapeutics announced that an abstract has been filed for presentation at the American College of Rheumatology Convergence 2026. This event serves as a key venue for sharing clinical updates in the rheumatology field. The news provides a specific upcoming date for stakeholders to monitor potential data releases related to the company's pipeline.